Date Filed | Type | Description |
06/08/2023 |
4
| Huber Reid M (Director) has filed a Form 4 on Tango Therapeutics, Inc.
Txns:
| Granted 5,000 shares
@ $0 Granted 30,000 options to buy
@ $3.55, valued at
$106.5k
|
|
01/20/2023 |
4/A
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC
Txns:
| Exercised 80,968 shares
@ $0 |
|
01/05/2023 |
4
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC
Txns:
| Exercised 87,196 shares
@ $0 |
|
09/02/2022 |
4
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC
Txns:
| Exercised 46,489 shares
@ $0 |
|
06/28/2022 |
4
| Huber Reid M (Director) has filed a Form 4 on Tango Therapeutics, Inc.
Txns:
| Granted 40,000 options to buy
@ $5.9, valued at
$236k
|
|
06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/06/2022 |
4
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC
Txns:
| Exercised 19,494 restricted stock units
@ $0 |
|
08/12/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
07/07/2021 |
4
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC
Txns:
| Granted 6,500 options to buy
@ $3.05, valued at
$19.8k
|
|
01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/16/2020 |
4
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC
Txns:
| Granted 6,500 options to buy
@ $8.42, valued at
$54.7k
|
|
06/14/2019 |
4
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC
Txns:
| Granted 25,000 options to buy
@ $1.96, valued at
$49k
|
|
07/18/2018 |
4
| Huber Reid M (EVP, Chief Scientific Officer) has filed a Form 4 on INCYTE CORP
Txns:
| Paid exercise price by delivering 448 shares
@ $70.19, valued at
$31.4k
|
|
07/05/2018 |
4
| Huber Reid M (EVP, Chief Scientific Officer) has filed a Form 4 on INCYTE CORP
Txns:
| Paid exercise price by delivering 284 shares
@ $68.28, valued at
$19.4k
Granted 22,772 options to buy
@ $68.62, valued at
$1.6M
|
|
06/18/2018 |
4
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC
Txns:
| Granted 10,000 options to buy
@ $9.8, valued at
$98k
|
|
02/22/2018 |
4
| Huber Reid M (EVP, Chief Scientific Officer) has filed a Form 4 on INCYTE CORP
Txns:
| Paid exercise price by delivering 1,064 shares
@ $86.03, valued at
$91.5k
Sold 1,958 shares
@ $85.55, valued at
$167.5k
|
|
01/25/2018 |
4
| Huber Reid M (EVP, Chief Scientific Officer) has filed a Form 4 on INCYTE CORP
Txns:
| Granted 12,128 options to buy
@ $94.63, valued at
$1.1M
Granted 21,167 options to buy
@ $95.34, valued at
$2M
|
|
12/05/2017 |
4
| Huber Reid M (EVP, Chief Scientific Officer) has filed a Form 4 on INCYTE CORP
Txns:
| Sold 696 shares
@ $98.01, valued at
$68.2k
|
|
09/15/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/07/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
06/15/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
05/09/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
03/01/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
02/28/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
01/19/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
01/11/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
11/10/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
10/11/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
08/02/2016 |
4
| Huber Reid M (EVP, Chief Scientific Officer) has filed a Form 4 on INCYTE CORP
Txns:
| Sold 10,000 shares
@ $87.96, valued at
$879.6k
|
|
07/19/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
06/17/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
02/18/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |